Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
57
¥ million (amount by which each loss narrowed)Wording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings reportSecond quarter of the fiscal year ending December 20265 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥273 million+8.7%
Operating profit¥-479 million
Ordinary income¥-481 million
Net income¥-483 million
Selling, general and administrative expenses¥753 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue¥21 million
- Decrease in cost of sales and selling, general and administrative expenses¥35 million
- Narrowing of operating loss¥57 million
- Narrowing of ordinary loss¥57 million
- Narrowing of net loss¥57 million
- Decrease in R&D expenses¥26 million
- Decrease in other expenses¥8 million
New initiatives
- Establishment of high-throughput screening technology for bispecific antibodies using DoppeLib and collaboration with multiple companies
- Development of biosimilar manufacturing facilities and new biosimilars with Alfresa Holdings, Kidswell Bio and Mycenax
- Launch of new projects under the business alliance with Axcelead Drug Discovery Partners Co., Ltd.
- Exploration of alliances and consideration of collaboration with pharmaceutical companies in Japan and overseas for the development of new biosimilars
Key KPIsA metric the company considers important as a management benchmark.
- Number of patients enrolled in the CBA-1205 clinical trial22 people
- Maximum dose of CBA-120530 mg/kg
- Duration of long-term SD continuation for CBA-12054 years+
- Number of employees63 people
Segment results
- Drug Discovery BusinessNet Sales¥0 million
- Drug Discovery Support BusinessNet Sales¥273 millionYear on year against the same period last year+8.7%
Number of employees
Number of Employees63
Record date30 June 2026
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings report |
| Fiscal Period Covered | Second quarter of the fiscal year ending December 2026 |
| Net Sales | ¥273 million (YoY +8.7%) |
| Operating profit | ¥-479 million |
| Ordinary income | ¥-481 million |
| Net income | ¥-483 million |
| Selling, general and administrative expenses | ¥753 million |
| Segment results | Segment Drug Discovery Business / Net Sales ¥0 million / Profit Not disclosed / Year on year against the same period last year Not disclosed, Segment Drug Discovery Support Business / Net Sales ¥273 million / Profit Not disclosed / Year on year against the same period last year 8.7 % |
| Breakdown of Factors Affecting the Change | Increase in revenue ¥21 million, Decrease in cost of sales and selling, general and administrative expenses ¥35 million, Narrowing of operating loss ¥57 million, Narrowing of ordinary loss ¥57 million, Narrowing of net loss ¥57 million, Decrease in R&D expenses ¥26 million, Decrease in other expenses ¥8 million |
| Key KPIs | Indicator name Number of patients enrolled in the CBA-1205 clinical trial / Value 22 people / Year on year against the same period last year Not disclosed, Indicator name Maximum dose of CBA-1205 / Value 30 mg/kg / Year on year against the same period last year Not disclosed, Indicator name Duration of long-term SD continuation for CBA-1205 / Value 4 years+ / Year on year against the same period last year Not disclosed, Indicator name Number of employees / Value 63 people / Year on year against the same period last year Not disclosed |
| Number of employees | Number of Employees 63 / Record date 30 June 2026 / Change during the period Not disclosed / Hiring plan Not disclosed |
| New initiatives | Establishment of high-throughput screening technology for bispecific antibodies using DoppeLib and collaboration with multiple companies, Development of biosimilar manufacturing facilities and new biosimilars with Alfresa Holdings, Kidswell Bio and Mycenax, Launch of new projects under the business alliance with Axcelead Drug Discovery Partners Co., Ltd., Exploration of alliances and consideration of collaboration with pharmaceutical companies in Japan and overseas for the development of new biosimilars |
Items this document does not state (19)
Gross Profit MarginOperating profit marginResults for the three months of the current quarterFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from research support services for pharmaceutical companies declined, while biosimilar-related revenue increased. Research and development expenses decreased mainly because clinical development-related costs and other expenses declined.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.